ReviewThe AAPS journal2014
Next generation ligand binding assays-review of emerging technologies' capabilities to enhance throughput and multiplexing.
Review in The AAPS journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Denaturation of firefly luciferase at heat shock temperatures captured in silico.Biophysical journal · 2025Article
- Elevated serum interferon-α2 associates with activity and flare risk in juvenile-onset systemic lupus erythematosus.Rheumatology (Oxford, England) · 2025Article
- Tensor-valued diffusion MRI detects brain microstructural abnormalities in HIV infected individuals with cognitive impairment.Scientific reports · 2024Article
- Tensor-valued diffusion MRI detects brain microstructure changes in HIV infected individuals with cognitive impairment.Research square · 2024Article
- How Can Proteomics Help to Elucidate the Pathophysiological Crosstalk in Muscular Dystrophy and Associated Multi-System Dysfunction?Proteomes · 2024Article
- A digital nanoplasmonic microarray immunosensor for multiplexed cytokine monitoring during CAR T-cell therapy from a leukemia tumor microenvironment model.Biosensors & bioelectronics · 2023Article
- In vitro selection of aptamers and their applications.Nature reviews. Methods primers · 2023Article
- A longitudinal analysis of brain extracellular free water in HIV infected individuals.Scientific reports · 2021Article
- Tumor Biomarker In-Solution Quantification, Standard Production, and Multiplex Detection.Journal of immunology research · 2021Review
- Detection and Digital Resolution Counting of Nanoparticles with Optical Resonators and Applications in Biosensing.Chemosensors (Basel, Switzerland) · 2018Article
- A Multi-site In-depth Evaluation of the Quanterix Simoa from a User's Perspective.The AAPS journal · 2017Article
- Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.Clinical rheumatology · 2017Article
- Behavior of ligand binding assays with crowded surfaces: Molecular model of antigen capture by antibody-conjugated nanoparticles.PloS one · 2017Article
- Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics.The AAPS journal · 2016Article
- Integrating cancer genomic data into electronic health records.Genome medicine · 2016Review
- Convergence of Highly Resolved and Rapid Screening Platforms with Dynamically Engineered, Cell Phenotype-Prescriptive Biomaterials.Current pharmacology reports · 2016Article
- Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies.Journal of immunology research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this manuscript is to provide a summary of the evaluation done by the Throughput and Multiplexing subteam on five emerging technologies: Single molecule array (Simoa™), Optimiser™, CyTOF® (Mass cytometry), SQIDLite™, and iLite™. Most of the information is presented with a minimum amount of published data and much is based on discussions with users and the vendor, to help provide the reader with an unbiased assessment of where the subteam sees each technology fitting best in the bioanalysis of large molecules. The evaluation focuses on technologies with advantages in throughput and multiplexing, but is wide enough to capture their strengths in other areas. While all platforms may be suited to support bioanalysis in the discovery space, because of their emergent nature, only Optimiser and SQIDLite are currently ready to be used in the regulated space. With the exception of Optimiser, each instrument/technology requires an up-front investment from the bioanalytical lab that will need justification during capital budget discussions. Ultimately, the platform choice should be driven by the quality of data, project needs, and the intended use of the data generated. In a time- and resource-constrained environment, it is not possible to evaluate all emergent technologies available in the market; we hope that this review gives the reader some of the information needed to decide which technology he/she may want to consider evaluating to support their drug development program in comparison to the options they already have in their hands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.